MAMohammad Sarwar Alam

Mohammad Sarwar Alam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohammad Sarwar Alam has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Design and synthesis of novel benzimidazole-tethered benzodiazepinones as promising anti-melanoma agents targeting JAK-3

    by Bharti Dhawan, Mohammad Sarwar Alam, Hinna Hamid, Swati Kumari, Gowsia Akhter, Aastha Mishra, Sabra Praveen, Ozair Alam, Animesh Majumdar, Shoaib Khan

  • Design and Synthesis of Benzimidazole Carboxamide Cysteine Protease Inhibitors as Promising Anti-leishmanial Agents

    by Gowsia Akhter, Hinna Hamid, Mirza A. Beg, Mushtaq A. Tantray, Bharti Dhawan, Mohammad Sarwar Alam, Angamuthu Selvapandiyan, Sayeed Ur Rehman, Kalicharan Sharma

    Introduction: More than 20 protozoan species of Leishmania are responsible for causing Leishmaniasis, an infection spread by blood-feeding phlebotomine sandflies. A narrow pool of drugs is currently available rendering the current drug stratagem to treat this infection . Development of novel, less toxic, and more effective regimens is thus a need of the hour. Design and synthesis of benzo[d]imidazole carboxamides as agents to combat Leishmaniasis are also required. Methods: 14 benzo[d]imidazole carboxamides were synthesized and gauged against L. donovani promastigotes and intramacrophage amastigote forms. All of the tested compounds exhibited significant anti-promastigote properties with IC50 well below 10 uM. Compounds 4a, 4b, and 4d, showing the highest anti-parasitic activity against promastigote forms (IC50 0.91- 1.33 μM), were also found to be associated with better anti-leishmanial potential (IC50 0.78- 1.67 μM) against the intramacrophage amastigotes comparable to Amphotericin-B (0.13 μM), a drug used for Leishmaniasis. Compound (4a), namely N-(2-(trifluoromethyl)-1Hbenzo[ d]imidazol-5-yl)benzo[d][1,3]-5-carboxamide-dioxole, was found to be most potent against L. donovani amastigotes among all the tested compounds, and demonstrated better antileishmanial properties (IC50 0.78 μM) when compared to the standard. Compound 4a was also assessed for its toxicity profile against THP-1 human monocytic cells. To establish the molecular target(s) in silico, molecular docking studies were performed against cysteine protease, a putative virulence factor of Leishmania parasites, and nucleoside diphosphate kinase, an enzyme with a critical role in nucleotide recycling, also associated with resistance in Leishmania strains. Compound 4a showed better binding affinity than the standard to these targets; furthermore, the molecular dynamic simulation studies further affirmed the stability of compound 4a, within the active site of the targets. In vitro, cysteine protease inhibitory activity (IC50 8.53 μM) using Bz-Arg-AMC hydrochloride fluorogenic peptide substrate established the promising potential of 4a as a cysteine protease inhibitor. Results: Computational ADMET analysis indicated appropriate pharmacokinetic profile and physicochemical characteristics for all members of the synthesized library. Conclusion: Both in vitro and in silico studies indicate that the synthesized imidazole carboxamides can act as potent hits and that N-(2-(trifluoromethyl)-1H-benzo[d]imidazol-5- yl)benzo[d][1,3]-5-carboxamide-dioxole 4a can be an effective hit molecule which can be further developed into potent lead molecule (s) to fight Leishmania donovani.


  • Zinc Triflate Catalyzed Tandem One-Pot Regioselective Synthesis of Highly Functionalized Pyrrole Derivatives

    by Mohammad Sarwar Alam, Balkrishna Ramchandra Kale, Hinna Hamid, Raju R Kale

    An efficient, zinc triflate catalyzed, tandem cyclization for the synthesis of highly functionalized pyrrole derivatives of potential medicinal significance has been developed. The four components—an arylamine, an aldehyde, acetylacetone, and nitromethane—were effectively cyclized in a single step with four different bonds (C–C and C–N). The readily available materials, broad substrate scope, excellent functional-group tolerance, mild conditions, scalability, and excellent yields of high-purity products are attractive features of this newly developed protocol.

  • Synthesis and Design of New 1,3,4‐Oxadiazole Benzimidazole Hybrids as Potential Antibacterial Agents Against MRSA by Targeting FabI

    by Gowsia Akhter, Hinna Hamid, Bharti Dhawan, Ayan Kumar Das, Mushtaq A. Tantray, Mohammad Sarwar Alam, Kalicharan Sharma

    The current investigation describes the synthesis of the 1,3,4‐oxadiazole benzimidazole hybrids 5 (a–m) as antibacterial agents against methicillin‐resistant Staphylococcus aureus (MRSA) by targeting the enoyl‐acyl carrier protein binding site of enoyl‐acyl carrier protein reductase (FabI). Compounds having better (2–6 µg/mL) minimum inhibitory concentrations (MIC) than ampicillin (100 µg/mL) in initial screening using the broth dilution method against S. aureus ( ATCC ‐29213) were further gauged for their antimicrobial potential against MRSA (ATCC 4330) using sultamicillin as a standard. 5‐(2‐(4‐Chlorophenyl)‐1 H ‐benzo[d]imidazol‐6‐yl)‐ N ‐phenyl‐1,3,4‐oxadiazol‐2‐amine ( 5a ) was found to be most potent against MRSA with a MIC of 6 µg/mL in comparison to sultamicillin (25 µg/mL). Furthermore, the time‐kill assay exhibited that compound 5a was bactericidal and demonstrated a high safety profile, as hemolysis caused in human red blood cells was insignificant (1.6%) at the concentration of 6 µg/mL (MIC × 3). To establish the molecular target of action, in silico molecular docking studies were performed against Sa FabI to reconnoiter the intervention of the molecules in the FAS‐II pathway. Compound 5a exhibited high binding affinity (−11.19) to the target; furthermore, the molecular dynamic simulation studies affirmed the stability of compound 5a , within the active site of the target. All compounds exhibited drug‐appropriate physicochemical characteristics and pharmacokinetic profiles as established by computational ADMET analysis. The study revealed that the synthesized library of small‐molecule oxadiazole benzimidazole hybrids holds promise for developing new antibacterial agents against MRSA infections.